



7<sup>th</sup> November, 2025

The Manager,  
Listing Compliance Department,  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1 Block-G  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400051

Corporate Office :  
406, Silver Oaks Comm. Complex,  
Opp. Arun Society, Paldi,  
Ahmedabad-380 007. Gujarat, India.  
Phone : 079-26584655  
CIN No. : L24231GJ2004PLC043861  
E-mail : info@sakarhealthcare.com  
Web : www.sakarhealthcare.com

Symbol: SAKAR

Dear Sir/Madam,

**Sub: Outcome of Board Meeting and Submission of Unaudited Financial Results & Limited Review Reports (Standalone & Consolidated) for the quarter ended on 30<sup>th</sup> September, 2025**

We refer to our letter dated 3rd November, 2025 informing the date of Meeting of the Board of Directors of the Company. Please note that the Board of Directors in their meeting held today, have taken on record the Unaudited Financial Results (Standalone & Consolidated) for the period ended on 30th September, 2025. These results have been reviewed by the Statutory Auditors of the Company and they have provided their limited review reports dated 7<sup>th</sup> November 2025.

We are enclosing herewith copy of the said Unaudited Financial Results and Limited Review Reports.


Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 30th September, 2025, please find enclosed the Integrated Filing (Financial) for the period ended 30th September, 2025.

The Board Meeting commenced at 11:30 a.m. and concluded at 12:30 p.m.

This is as per Regulation – 33 and other applicable provisions of the SEBI (LODR) Regulations, 2015.

Thanking you.

Yours faithfully,  
for SAKAR HEALTHCARE LIMITED

  
SANJAY S. SHAH  
MANAGING DIRECTOR  
(DIN: 01515296)



Encl: As above.

### STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND SIX MONTHS ENDED ON 30<sup>TH</sup> SEPTEMBER, 2025

(Rs. In lakh)

Particulars		Quarter ended on			Half Year ended on (Cumulative)		Previous Year ended on 31-03-2025
		30-09-2025	30-06-2025	30-09-2024	30-09-2025	30-09-2024	
(Refer Notes Below)		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	5756.04	5273.62	4277.81	11029.66	8392.58	17758.47
2	Other income	121.46	39.39	37.29	160.85	83.27	131.27
3	<b>Total Income (1+2)</b>	<b>5877.50</b>	<b>5313.01</b>	<b>4315.10</b>	<b>11190.51</b>	<b>8475.85</b>	<b>17889.74</b>
4	<b>Expenses</b>						
	a. Cost of Materials consumed	2961.01	2875.73	2201.30	5836.74	4451.00	9546.73
	b. Purchases of stock-in-trade	-	-				-
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	79.63	19.51	88.47	99.14	44.91	(1320.46)
	d. Employee benefits expense	834.19	754.96	545.52	1589.15	1083.97	3164.85
	e. Finance costs	152.68	214.26	164.40	366.94	304.21	853.50
	f. Depreciation & amortisation expense	568.38	557.23	511.90	1125.61	1017.65	2088.22
	g. Other expenses	745.82	352.84	292.40	1098.66	592.69	1399.03
	<b>Total Expenses</b>	<b>5341.71</b>	<b>4774.53</b>	<b>3803.99</b>	<b>10116.24</b>	<b>7494.43</b>	<b>15731.87</b>
5	Profit before exceptional items and tax (3-4)	535.79	<b>538.48</b>	511.11	1074.27	981.42	<b>2157.87</b>
6	Exceptional items						5.14
7	Profit before tax (5-6)	535.79	538.48	511.11	1074.27	981.42	2152.73
8	Tax expense:						
	Current tax	100.90	90.29	85.18	191.19	164.10	366.03
	Deferred tax	81.81	71.35	31.48	153.16	260.59	402.53
	MAT Credit Entitlement	(100.90)	(90.29)	(85.18)	(191.19)	(164.10)	(366.03)
9	Profit for the period from continuing operations (7-8)	453.98	<b>467.13</b>	479.63	921.11	720.83	<b>1750.20</b>
10	Profit from discontinuing operations before Tax	-	-	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-	-	-
12	Profit from Discontinuing operations (after tax) (10-11)	-	-	-	-	-	-
13	<b>Profit for the period (9+12)</b>	<b>453.98</b>	<b>467.13</b>	<b>479.63</b>	<b>921.11</b>	<b>720.83</b>	<b>1750.20</b>







**Healthcare Ltd.**

[CIN: L24231GJ2004PLC043861]

**Reg. Office:** Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213

**Phone:** 02717-250477 **Fax:** 02717-251621 **Email:** [info@sakarhealthcare.com](mailto:info@sakarhealthcare.com) **Web:** [www.sakarhealthcare.com](http://www.sakarhealthcare.com)

Particulars		Quarter ended on			Half Year ended on (Cumulative)		Previous Year ended on 31-03-2025
		30-09-2025	30-06-2025	30-09-2024	30-09-2025	30-09-2024	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
14	<b>Other Comprehensive Income</b>						
	<i>Items that will not be reclassified subsequently to profit or loss</i>						
	Re-measurement gains/(losses) on defined benefit plans	(3.70)	(3.70)	(10.93)	(7.40)	(14.63)	(16.23)
	Income tax relating to items that will not be reclassified to profit or loss	1.03	1.03	3.04	2.06	4.07	4.52
	<i>Items that will be reclassified subsequently to profit or loss</i>						
	Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Other Comprehensive Income, net of tax</b>	<b>(2.67)</b>	<b>(2.67)</b>	<b>(7.89)</b>	<b>(5.34)</b>	<b>(10.56)</b>	<b>(11.71)</b>
15	<b>Total Comprehensive Income for the period (13+14)</b>	<b>451.31</b>	<b>464.46</b>	<b>471.74</b>	<b>915.77</b>	<b>710.27</b>	<b>1738.49</b>
16	Paid-up equity shares capital (Face Value per share Rs. 10/-)	<b>2224.99</b>	<b>2224.99</b>	<b>2174.99</b>	<b>2224.99</b>	<b>2174.99</b>	<b>2194.99</b>
17	Reserves excluding Revaluation Reserves						<b>26073.12</b>
18	Earnings Per Share of Rs. 10/- each (for continuing operations)						
	- Basic	2.03	2.11	2.17	4.14	3.27	7.97
	- Diluted	2.03	2.11	2.16	4.14	3.25	7.95
19	Earnings Per Share of Rs. 10/- each (for discontinued operations)						
	- Basic	0.00	0.00	-	-	-	0.00
	- Diluted	0.00	0.00	-	-	-	0.00
20	Earnings Per Share of Rs. 10/- each (for discontinued & continuing operations)						
	- Basic	2.03	2.11	2.17	4.14	3.27	7.97
	- Diluted	2.03	2.11	2.16	4.14	3.25	7.95



**Corporate Office:** 406, silver Oaks Commercial Complex, Opp. Arun Society, Paldi, Ahmedabad – 380 007  
**Phone:** 079-26584655 **Fax:** 079-26588054

## STATEMENT OF STANDALONE ASSETS AND LIABILITIES

		(Rs. In lakh)	
Sr.No.	Particulars	As at 30-09-2025 (Unaudited)	As at 31-03-2025 (Audited)
	<b>ASSETS</b>		
1	<b>Non-Current Assets</b>		
	Property, plant and equipment	31711.70	30434.93
	Capital work-in-progress	1703.36	1670.35
	Investment property		
	Goodwill		
	Other intangible Assets	765.64	461.07
	Intangible Assets under development		
	Biological Assets other than bearer plants		
	Non-Current Financial Assets:		
	(i) Investments, Non-Current	1.00	1.00
	(ii) Trade receivables, Non-Current		
	(iii) Loans, Non-Current	30.06	30.06
	Deferred tax Assets (net)		
	Other Non-Current Assets	1186.11	56.97
	<b>Total Non-Current Assets</b>	<b>35397.87</b>	<b>32654.38</b>
2	<b>Current Assets</b>		
	Inventories	4452.65	4359.24
	Current financial asset:		
	(i) Current investments	-	-
	(ii) Trade receivables, Current	3198.52	3072.30
	(iii) Cash and cash equivalents	0.64	9.96
	(iv) Bank balance other than above	20.77	20.77
	(v) Loans, Current	7.72	7.72
	(vi) Other Current financial Assets		
	Current tax Assets (net)		
	Other Current Assets	1790.14	1410.25
	<b>Total Current Assets</b>	<b>9470.44</b>	<b>8880.24</b>
	<b>TOTAL ASSETS</b>	<b>44868.31</b>	<b>41534.62</b>



	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Equity</b>		
	Equity share capital	2224.99	2194.99
	Other Equity	28108.82	26073.12
	Money Received Against Share Warrant		288.00
	<b>Total Equity</b>	<b>30333.81</b>	<b>28556.11</b>
<b>2</b>	<b>Liabilities</b>		
	<b>Non-Current Liabilities</b>		
	Non-Current financial Liabilities:		
	(i) Borrowings, Non-Current	4525.60	5359.42
	(ii) Trade payables, Non-Current		
	(a) total outstanding dues of micro enterprises and small enterprises		
	(b) total outstanding dues of creditors other than micro enterprises and small enterprises		
	(iii) Other Non-Current financial Liabilities		
	Provisions, Non-Current	274.19	266.04
	Deferred tax Liabilities (net)	996.41	1034.44
	Other Non-Current Liabilities		
	<b>Total Non-Current Liabilities</b>	<b>5796.21</b>	<b>6659.90</b>
	<b>Current Liabilities</b>		
	Current financial Liabilities:		
	(i) Borrowings, Current	2660.55	2136.05
	(ii) Trade payables, Current		
	(a) total outstanding dues of micro enterprises and small enterprises		
	(b) total outstanding dues of creditors other than micro enterprises and small enterprises	3602.77	2106.66
	(iii) Other Current financial Liabilities	1322.00	1142.00
	Other Current Liabilities	937.92	801.30
	Provisions, Current		-
	Current tax Liabilities (Net)	215.05	132.60
	<b>Total Current Liabilities</b>	<b>8738.29</b>	<b>6318.61</b>
	<b>Total Liabilities</b>	<b>14534.49</b>	<b>12978.51</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>44868.31</b>	<b>41534.62</b>







**Healthcare Ltd.**

[CIN: L24231GJ2004PLC043861]

Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213

Phone: 02717-250477 Fax: 02717-251621 Email: [info@sakarhealthcare.com](mailto:info@sakarhealthcare.com) Web: [www.sakarhealthcare.com](http://www.sakarhealthcare.com)

**STATEMENT OF CASH FLOWS FOR THE PERIOD  
FROM 1<sup>ST</sup> APRIL, 2025 TO 30<sup>TH</sup> SEPTEMBER, 2025 (HALF-YEAR)**

Particulars	(Rs. In Lakh)	
	For the Half year ended on 30th September, 2025	For the Half year ended on 30th September, 2024
Profit before Taxes	1074.27	981.42
<b>Adjustments:</b>		
Depreciation	1125.61	1017.64
Interest Expense	355.38	271.53
Provision for Doubtful Debts	2.24	1.68
Unrealized Loss/(Gain) On Mutual Fund		-
Amortized Loan Processing Fes	2.88	2.88
Actuarial gain/(Loss) Employee Benefit Expenses	(7.40)	(14.63)
<b>Changes in Working Capital</b>		
Inventories	(93.41)	(612.58)
Financial assets		
- Trade receivables	(128.47)	(304.41)
- Loans and Advances		
- Short Term Investments		
Other current assets	(379.89)	37.59
Other Non- Current Assets		
MAT Credit		-
Financial assets		
- Loans and Advances		
Other non-current assets	(1129.14)	(387.02)
Financial liabilities		
- Borrowings	524.50	1056.22
- Trade Payables	1496.11	(187.44)
- Other financial liabilities	316.62	259.40
Other current liabilities		
Provisions	177.94	50.55
<b>Cashflow from Operating Activity before Taxes</b>	<b>3337.24</b>	<b>2172.83</b>
Net Tax Paid	(278.53)	(63.08)
<b>Net Cashflow from Operating Activity</b>	<b>3058.71</b>	<b>2109.75</b>
Cashflow from Investing Activity		
Purchase of Property, Plant & Equipments	(2739.95)	(1305.15)
Proceed From Sale of Investment		-
Purchase of Mutual Fund		
Purchase of Intangible Assets		
<b>Net Cashflow from Investing Activity</b>	<b>(2739.95)</b>	<b>(1305.15)</b>
Cashflow from Financing Activity		
Proceeds from issue of shares	864.00	-
Proceeds / (Repayment) of Borrowings	(833.82)	(524.01)
Interest Paid	(355.38)	(271.53)
Payment Of Loan Processing Fees	(2.88)	(2.88)
<b>Net Cashflow from Financing Activity</b>	<b>(328.08)</b>	<b>(798.42)</b>
<b>Net Cash Inflow / (Outflow)</b>	<b>(9.32)</b>	<b>6.18</b>
Opening Cash and Cash Equivalent	9.96	25.59
<b>Closing Cash and Cash Equivalent</b>	<b>0.64</b>	<b>31.76</b>

for SAKAR HEALTHCARE LIMITED



*Sanjay S. Shah*  
**SANJAY S. SHAH**  
**MANAGING DIRECTOR**  
(DIN : 01515296)

Date: 7<sup>th</sup> November, 2025  
Place: Ahmedabad

**Corporate Office:** 406, silver Oaks Commercial Complex, Opp. Arun Society, Paldi, Ahmedabad – 380 007  
**Phone:** 079-26584655 **Fax:** 079-26588054



**Healthcare Ltd.**

[CIN: L24231GJ2004PLC043861]

**Reg. Office:** Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213

**Phone:** 02717-250477 **Fax:** 02717-251621 **Email:** [info@sakarhealthcare.com](mailto:info@sakarhealthcare.com) **Web:** [www.sakarhealthcare.com](http://www.sakarhealthcare.com)

**Notes:**

1	The Company is operating only in one segment. Hence segment reporting is not given.
2	The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
3	The Company has a wholly owned subsidiary vis. M/s. Sakar Oncology Private Limited. Other than this, the Company does not have any subsidiary/ associate.
4	Provision for taxation/deferred taxation, if any, will be made at the year end.
5	Figures, wherever required, are regrouped / rearranged.
6	The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 7 <sup>th</sup> November, 2025.

**Date:** 7th November, 2025

**Place:** Ahmedabad

**for SAKAR HEALTHCARE LIMITED**



**SANJAY S. SHAH**  
**MANAGING DIRECTOR**  
**(DIN : 01515296)**

**Corporate Office:** 406, silver Oaks Commercial Complex, Opp. Arun Society, Paldi, Ahmedabad – 380 007  
**Phone:** 079-26584655 **Fax:** 079-26588054

**LIMITED REVIEW REPORT**

**Review Report to the Board of Directors of Sakar Healthcare Limited**


We have reviewed the accompanying statement of unaudited standalone financial results of Sakar Healthcare Limited for the period quarter ended 30<sup>th</sup> September 2025, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, as amended ("the Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement(s). A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For J S Shah & Co  
Chartered Accountants  
FRN : 132059W



Jaimin S Shah  
Partner

Membership No. : 138488  
UDIN : 25138488BMIBFS8643  
Place : Ahmedabad  
Date : 07.11.2025





**STATEMENT OF CONSOLIDATED UNAUDITED RESULTS  
FOR THE QUARTER ENDED ON 30<sup>TH</sup> SEPTEMBER, 2025**

(Rs. In lakh)

(Refer Notes Below)		Quarter ended on			Half Year ended on (Cumulative)		Previous Year ended on 31-03-2025 (Audited)
		30-09-2025	30-06-2025	30-09-2024	30-09-2025	30-09-2024	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
1	Revenue from operations	5756.04	5273.62	4277.81	11029.66	8392.58	17758.47
2	Other income	121.46	39.39	37.29	160.85	83.27	131.27
3	<b>Total Income (1+2)</b>	<b>5877.50</b>	<b>5313.01</b>	<b>4315.10</b>	<b>11190.51</b>	<b>8475.85</b>	<b>17889.74</b>
4	<b>Expenses</b>						
	a. Cost of Materials consumed	2961.01	2875.73	2201.30	5836.74	4451.00	9546.73
	b. Purchases of stock-in-trade	-	-				-
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	79.63	19.51	88.47	99.14	44.91	(1320.46)
	d. Employee benefits expense	834.19	754.96	545.52	1589.15	1083.97	3164.85
	e. Finance costs	152.68	214.26	164.40	366.94	304.21	853.50
	f. Depreciation & amortisation expense	568.38	557.23	511.90	1125.61	1017.65	2088.22
	g. Other expenses	745.82	352.84	292.40	1098.66	592.69	1399.03
	<b>Total Expenses</b>	<b>5341.71</b>	<b>4774.53</b>	<b>3803.99</b>	<b>10116.24</b>	<b>7494.43</b>	<b>15731.87</b>
5	Profit before exceptional items and tax (3-4)	<b>535.79</b>	<b>538.48</b>	<b>511.11</b>	<b>1074.27</b>	<b>981.42</b>	<b>2157.87</b>
6	Exceptional items						5.14
7	Profit before tax (5-6)	<b>535.79</b>	<b>538.48</b>	<b>511.11</b>	<b>1074.27</b>	<b>981.42</b>	<b>2152.73</b>
8	Tax expense:						
	Current tax	100.90	90.29	85.18	191.19	164.10	366.03
	Deferred tax	81.81	71.35	31.48	153.16	260.59	402.53
	MAT Credit Entitlement	(100.90)	(90.29)	(85.18)	(191.19)	(164.10)	(366.03)
9	Profit for the period from continuing operations (7-8)	453.98	<b>467.13</b>	479.63	921.11	720.83	<b>1750.20</b>
10	Profit from discontinuing operations before Tax	-	-	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-	-	-
12	Profit from Discontinuing operations (after tax) (10-11)	-	-	-	-	-	-
13	Share of profit of associates and joint ventures accounted for using equity method			-	-	-	-
14	Profit for the period (9+12+13)	453.98	<b>467.13</b>	479.63	921.11	720.83	<b>1750.20</b>
	Attributable to owner of parent	453.98	<b>467.13</b>	479.63	921.11	720.83	<b>1750.20</b>
	Attributable to Non-controlling interests		-	-	-	-	-



Particulars	Quarter ended on			Half Year ended on (Cumulative)		Previous Year ended on 31-03-2025
	30-09-2025	30-06-2025	30-09-2024	30-09-2025	30-09-2024	
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
(Refer Notes Below)						
15 Other Comprehensive Income						
Items that will not be reclassified subsequently to profit or loss						
Re-measurement gains/(losses) on defined benefit plans	(3.70)	(3.70)	(10.93)	(7.40)	(14.63)	(16.23)
Income tax relating to items that will not be reclassified to profit or loss	1.03	1.03	3.04	2.06	4.07	4.52
Items that will be reclassified subsequently to profit or loss						
Income tax relating to items that will be reclassified to profit or loss	-		-	-	-	
Other Comprehensive Income, net of tax	(2.67)	(2.67)	(7.89)	(5.34)	(10.56)	(11.71)
Attributable to owner of parent	(2.67)	(2.67)	(7.89)	(5.34)	(10.56)	(11.71)
Attributable to Non-controlling interests						
16 Total Comprehensive Income for the period (14+15)	451.31	464.46	471.74	915.77	710.27	1738.49
Attributable to owner of parent	451.31	464.46	471.74	915.77	710.27	1738.49
Attributable to Non-controlling interests						
17 Paid-up equity shares capital (Face Value per share Rs. 10/-)	2224.99	2224.99	2174.99	2224.99	2174.99	2194.99
18 Reserves excluding Revaluation Reserves						26064.60
19 Earnings Per Share of Rs. 10/- each (for continuing operations)						
- Basic	2.03	2.11	2.17	4.14	3.27	7.97
- Diluted	2.03	2.11	2.16	4.14	3.25	7.95
20 Earnings Per Share of Rs. 10/- each (for discontinued operations)						
- Basic	0.00	0.00	-	-	-	0.00
- Diluted	0.00	0.00	-	-	-	0.00
21 Earnings Per Share of Rs. 10/- each (for discontinued & continuing operations)						
- Basic	2.03	2.11	2.17	4.14	3.27	7.97
- Diluted	2.03	2.11	2.16	4.14	3.25	7.95





## STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES

(Rs. In lakh)			
Sr.No.	Particulars	As at 30-09-2025 (Unaudited)	As at 31-03-2025 (Audited)
	<b>ASSETS</b>		
1	<b>Non-Current Assets</b>		
	Property, plant and equipment	31711.70	30434.93
	Capital work-in-progress	1703.36	1670.35
	Investment property		
	Goodwill		
	Other intangible Assets	765.64	461.07
	Intangible Assets under development		
	Biological Assets other than bearer plants		
	Non-Current Financial Assets:		
	(i) Investments, Non-Current		
	(ii) Trade receivables, Non-Current		
	(iii) Loans, Non-Current	30.06	30.06
	Deferred tax Assets (net)		
	Other Non-Current Assets	1186.11	56.97
	<b>Total Non-Current Assets</b>	<b>35396.87</b>	<b>32653.38</b>
2	<b>Current Assets</b>		
	Inventories	4452.65	4359.24
	Current financial asset:		
	(i) Current investments		
	(ii) Trade receivables, Current	3198.52	3072.30
	(iii) Cash and cash equivalents	0.83	10.16
	(iv) Bank balance other than above	20.77	20.77
	(v) Loans, Current		
	(vi) Other Current financial Assets		
	Current tax Assets (net)		
	Other Current Assets	1790.14	1410.25
	<b>Total Current Assets</b>	<b>9462.91</b>	<b>8872.72</b>
	<b>TOTAL ASSETS</b>	<b>44859.78</b>	<b>41526.10</b>



		(Rs. In lakh)	
Sr.No.	Particulars	As at 30-09-2025 (Unaudited)	As at 31-03-2025 (Audited)
	<b>EQUITY AND LIABILITIES</b>		
1	<b>Equity</b>		
	Equity share capital	2224.99	2194.99
	Other Equity	28100.30	26064.60
	Money Received Against Share Warrant		288.00
	<b>Total Equity</b>	<b>30325.29</b>	<b>28547.59</b>
2	<b>Liabilities</b>		
	<b>Non-Current Liabilities</b>		
	Non-Current financial Liabilities:		
	(i) Borrowings, Non-Current	4525.60	5359.42
	(ii) Trade payables, Non-Current		
	(a) total outstanding dues of micro enterprises and small enterprises		
	(b) total outstanding dues of creditors other than micro enterprises and small enterprises		
	(iii) Other Non-Current financial Liabilities		
	Provisions, Non-Current	274.19	266.04
	Deferred tax Liabilities (net)	996.41	1034.44
	Other Non-Current Liabilities		
	<b>Total Non-Current Liabilities</b>	<b>5796.20</b>	<b>6659.90</b>
	<b>Current Liabilities</b>		
	Current financial Liabilities:		
	(i) Borrowings, Current	2660.55	2136.05
	(ii) Trade payables, Current		
	(a) total outstanding dues of micro enterprises and small enterprises		
	(b) total outstanding dues of creditors other than micro enterprises and small enterprises	3602.77	2106.66
	(iii) Other Current financial Liabilities	1322.00	1142.00
	Other Current Liabilities	937.92	801.30
	Provisions, Current		
	Current tax Liabilities (Net)	215.05	132.60
	<b>Total Current Liabilities</b>	<b>8738.29</b>	<b>6318.61</b>
	<b>Total Liabilities</b>	<b>14534.49</b>	<b>12978.51</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>44859.78</b>	<b>41526.10</b>







**Healthcare Ltd.**

[CIN: L24231GJ2004PLC043861]

Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213

Phone: 02717-250477 Fax: 02717-251621 Email: [info@sakarhealthcare.com](mailto:info@sakarhealthcare.com) Web: [www.sakarhealthcare.com](http://www.sakarhealthcare.com)

**STATEMENT OF CONSOLIDATED CASH FLOWS FOR THE PERIOD  
FROM 1<sup>ST</sup> APRIL, 2025 TO 30<sup>TH</sup> SEPTEMBER, 2025 (HALF-YEAR)**

Particulars	For the Half year ended on 30th September, 2024	For the Half year ended on 30th September, 2023
Profit before Taxes	1074.27	981.42
<b>Adjustments:</b>		
Depreciation	1125.61	1017.64
Interest Expense	355.38	271.53
Provision for Doubtful Debts	2.24	1.68
Unrealised Loss/(Gain) On Mutual Fund		-
Amortised Loan Processing Fes	2.88	2.88
Changes in Other Equity	(7.40)	(14.63)
<b>Changes in Working Capital</b>		
Inventories	(93.41)	(612.58)
Financial assets		
- Trade receivables	(128.47)	(304.41)
- Loans and Advances		
- Short Term Investments		
Other current assets	(379.89)	37.59
MAT Credit		-
Financial assets		
- Loans and Advances		
Other non-current assets	(1129.14)	(387.02)
Financial liabilities		
- Borrowings	524.50	1056.22
- Trade Payables	1496.11	(187.44)
- Other financial liabilities	316.62	259.40
Other current liabilities		
Provisions	177.94	50.55
<b>Cashflow from Operating Activity before Taxes</b>	<b>3337.24</b>	<b>2172.83</b>
Net Tax Paid	(278.53)	(63.08)
<b>Net Cashflow from Operating Activity</b>	<b>3058.71</b>	<b>2109.75</b>
<b>Cashflow from Investing Activity</b>		
Purchase of Property, Plant & Equipments	(2739.95)	(1305.15)
Purchase of Mutual Fund		
Purchase of Intangible Assets		
Proceed from Sale of Investment		
<b>Net Cashflow from Investing Activity</b>	<b>(2739.95)</b>	<b>(1305.15)</b>
<b>Cashflow from Financing Activity</b>		
Proceeds from issue of shares	864.00	-
Proceeds / (Repayment) of Borrowings	(833.82)	(524.01)
Payment Of Loan Processing Fees	(2.88)	(2.88)
Interest Paid	(355.38)	(271.53)
<b>Net Cashflow from Financing Activity</b>	<b>(328.08)</b>	<b>(798.42)</b>
<b>Net Cash Inflow / (Outflow)</b>	<b>(9.32)</b>	<b>6.18</b>
Opening Cash and Cash Equivalent	10.16	25.79
<b>Closing Cash and Cash Equivalent</b>	<b>0.84</b>	<b>31.96</b>

for SAKAR HEALTHCARE LIMITED



**SANJAY S. SHAH**  
**MANAGING DIRECTOR**  
(DIN : 01515296)

Date: 7<sup>th</sup> November 2025

Place: Ahmedabad

**Corporate Office: 406, silver Oaks Commercial Complex, Opp. Arun Society, Paldi, Ahmedabad – 380 007**  
**Phone: 079-26584655 Fax: 079-26588054**



**Healthcare Ltd.**

[CIN: L24231GJ2004PLC043861]

**Reg. Office:** Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213

**Phone:** 02717-250477 **Fax:** 02717-251621 **Email:** [info@sakarhealthcare.com](mailto:info@sakarhealthcare.com) **Web:** [www.sakarhealthcare.com](http://www.sakarhealthcare.com)

**Notes:**

1	The Company is operating only in one segment. Hence segment reporting is not given.
2	The consolidated Unaudited financial results of the Company are comprising of its subsidiary M/s. Sakar Oncology Private Limited.
3	The Consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 “Interim Financial Reporting” as prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
4	Provision for taxation/deferred taxation, if any, will be made at the year end.
5	Figures, wherever required, are regrouped / rearranged.
6	The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 7 <sup>th</sup> November 2025.

**Date:** 7th November 2025

**Place:** Ahmedabad

**for SAKAR HEALTHCARE LIMITED**



**SANJAY S. SHAH**  
**MANAGING DIRECTOR**  
**(DIN : 01515296)**



**LIMITED REVIEW REPORT**

**TO THE BOARD OF DIRECTORS OF SAKAR HEALTHCARE LIMITED**

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of Sakar Healthcare Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/ (loss) after tax and total comprehensive income / loss of its associates and joint ventures for the Quarter ended 30<sup>th</sup> September 2025 and for the period from 01.04.2025 to 30.09.2025 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"). Attention is drawn to the fact that the consolidated figures for the corresponding Quarter ended 30<sup>th</sup> September 2024 and the corresponding period from 01.04.2024 to 30.09.2024, as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to review.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.




4. The Statement includes the results of the following entities:

1) Sakar Oncology Private Limited

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information of Sakar Oncology Private Limited subsidiaries included in the consolidated unaudited financial results, whose interim financial information reflects, total revenues of Nil, total net profit after tax of Nil, total comprehensive income of Nil for the quarter ended September 30, 2025, as considered in the Statement. This interim financial information has been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters

For J S Shah & Co  
Chartered Accountants  
FRN : 132059W



Jaimin S Shah  
Partner

Membership No. : 138488  
UDIN : 25138488BMIBFT6605  
Place : Ahmedabad  
Date : 07.11.2025





**B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.**

Statement on deviation / variation in utilisation of funds raised	
Name of listed entity	Sakar Healthcare Limited
Mode of Fund Raising	Preferential Issue (Conversion of Warrants into Equity Shares)
Date of Raising Funds	17-06-2025
Amount Raised	Rs. 8,64,00,000/-
Report filed for Quarter ended	30-09-2025
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	Not applicable
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not applicable
If Yes, Date of shareholder Approval	Not applicable
Explanation for the Deviation / Variation	Not applicable
Comments of the Audit Committee after review	Not applicable
Comments of the auditors, if any	Not applicable

Objects for which funds have been raised and where there has been a deviation, in the following table:

Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised till 30-09-2025	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
Capital expenditure for Procurement of Lipid Complex Injections Machinery and Equipments/Utilities with electrification for Oncology unit	N.A.	7,09,35,000	N.A.	7,09,35,000	NIL	The Funds have been utilized in total

**Deviation or variation could mean:**

- (a) Deviation in the objects or purposes for which the funds have been raised or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
- (c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc



**C. DISCLOSURE OF OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES:**

Not Applicable

Sr. No.	Particulars	in INR crore
<b>1.</b>	<b>Loans / revolving facilities like cash credit from banks / financial institutions</b>	
A.	Total amount outstanding as on date	0
B.	Of the total amount outstanding, amount of default as on date	0
<b>2.</b>	<b>Unlisted debt securities i.e. NCDs and NCRPS</b>	
A.	Total amount outstanding as on date	0
B.	Of the total amount outstanding, amount of default as on date	0
<b>3.</b>	<b>Total financial indebtedness of the listed entity including short-term and long-term debt</b>	0

**D. DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE HALF YEAR ENDED 30<sup>TH</sup> JUNE, 2025 (applicable only for half-yearly filings i.e., 2<sup>nd</sup> and 4<sup>th</sup> quarter) :**

Please Refer Annexure 1

**E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4<sup>th</sup> quarter)**

:Not Applicable

for SAKAR HEALTHCARE LIMITED

Date : 7<sup>th</sup> November, 2025  
Place: Ahmedabad




*Sanjay S. Shah*  
**SANJAY S. SHAH**  
MANAGING DIRECTOR  
DIN: 01515296




Annex - I


DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR HALF PERIOD ENDED 30<sup>TH</sup> SEPTEMBER, 2025

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.																			
S. No	Details of the party (listed entity/subsidiary) entering into the transaction		Details of the counterparty		Type of related party transaction (see Note 5)	Value of the related party transaction as approved by the audit committee (see Note 6a)	Value of the related party transaction ratified by the audit committee (see Note 6b)	Value of transaction during the reporting period (see Note 6c)	In case monies are due to either party as a result of the transaction (see Note 1)		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments	Details of the loans, inter-corporate deposits, advances or investments					Purpose for which the funds will be utilised by the ultimate recipient of funds (end-use)		
	Name	PAN	Name	PAN					Relationship of the counterparty with the listed entity or its subsidiary	Opening balance		Closing balance	Nature of indebtedness (loan/issuance of debt/ any other etc.)	Cost (see Note 7)	Tenure	Interest Rate (%)		Nature (loan/advance/inter-corporate deposit/investment)	Secured/unsecured
1	Sakar Healthcare Limited		Sanjay S. Shah		Managing Director	90.00 Lacs	90.00 Lacs	90.00 Lacs	-	-	-	-	-	-	-	-	-	-	
2	Sakar Healthcare Limited		Sanjay S. Shah		Managing Director	1.63 Lacs	1.63 Lacs	1.63 Lacs	1.63 Lacs	1.63 Lacs	-	-	-	-	-	-	-	-	
3	Sakar Healthcare Limited		Rita S. Shah		Non-Executive Director	9.00 Lacs	9.00 Lacs	9.00 Lacs	-	-	-	-	-	-	-	-	-	-	
4	Sakar Healthcare Limited		Aarsh S. Shah		Jt. Managing Director	72.00 Lacs	72.00 Lacs	72.00 Lacs	-	-	-	-	-	-	-	-	-	-	
5	Sakar Healthcare		Ayushi S. Shah		Administrative Executive	-	-	-	-	-	-	-	-	-	-	-	-	-	





Cont'd Sh



[illegible]